Mescaline is unlikely to kill you, but it is not without risk. No human deaths have been conclusively attributed to mescaline toxicity alone, and researchers who have extrapolated from animal data estimate that a person would need to consume an extraordinarily large amount to reach a lethal dose. That said, “not lethal” and “safe” are different things. Mescaline raises your heart rate and blood pressure, reliably causes nausea and vomiting at higher doses, and carries real psychological risks, especially for people with a history of mental health conditions.
Physical Toxicity and Lethal Dose
Mescaline has been studied in animals across multiple species, and the lethal dose varies widely depending on the animal and how the drug is administered. In mice given mescaline orally, the dose that killed half the test population was 880 mg per kilogram of body weight. Dogs were far more sensitive, with a lethal dose of just 54 mg/kg when injected intravenously. For humans, the lowest dose known to produce any psychoactive effect has been estimated at about 2.5 mg/kg by injection, while a typical strong oral dose is around 400 to 500 mg total. Given that gap between an active dose and a lethal one, researchers have concluded it would be very difficult to consume enough mescaline to cause death.
The rare serious medical events linked to peyote (the cactus that naturally contains mescaline) have generally been indirect. There are case reports of Mallory-Weiss tears, which are lacerations in the esophagus caused by violent vomiting, and cases of botulism from improperly stored peyote buttons. The drug itself, at doses people actually take, tends to produce what toxicologists call a mild intoxication.
Nausea and Vomiting Are Common
The most predictable physical side effect of mescaline is gastrointestinal distress. Nausea, vomiting, and loss of appetite are frequently reported, particularly with natural peyote, which contains additional alkaloids and plant material that irritate the stomach. In a controlled clinical trial testing mescaline hydrochloride in capsule form, the 800 mg dose “already produced substantial adverse effects, including relevant nausea and vomiting,” and researchers expected an even higher dose to be poorly tolerated. Even at moderate doses (200 to 400 mg), some nausea is typical. This is not a minor inconvenience for many users; it can be intense and prolonged, often occurring during the first hour or two as the drug takes effect.
Cardiovascular Effects
Mescaline acts on serotonin receptors in the brain, primarily the 5-HT2A receptor, which is the same receptor targeted by other classical psychedelics like LSD and psilocybin. One consequence of this activity is cardiovascular stimulation. A 2023 study comparing mescaline, LSD, and psilocybin in 32 healthy subjects found that a 500 mg dose of mescaline raised systolic blood pressure and heart rate to a degree comparable to the other two substances. Interestingly, the lower 300 mg dose actually produced a greater heart rate increase than the 500 mg dose, a finding researchers noted but could not fully explain.
Mescaline has also been found to induce blood vessel constriction in the brain and to trigger shape changes in platelets (the blood cells involved in clotting). What these effects mean for someone with healthy blood vessels is probably not much. But clinical trials with psychedelics have consistently excluded people with cardiovascular disease, which means there is essentially no safety data for anyone with a heart condition, high blood pressure, or a history of stroke. The reassuring safety profile that exists applies only to healthy individuals.
Psychological Risks
The psychological experience of mescaline lasts 8 to 12 hours, considerably longer than psilocybin, and the intensity of that experience is the primary source of risk for most people. Acute effects at a strong dose include vivid visual distortions, altered sense of time, and powerful emotional states that can swing between euphoria and terror. A difficult experience (“bad trip”) can involve extreme anxiety, paranoia, or panic that persists for hours.
Beyond the acute experience, there is a small but real risk of Hallucinogen Persisting Perception Disorder (HPPD), a condition in which visual disturbances from the drug experience continue to recur long after the drug has left the body. HPPD is rare. The DSM-5 suggests a prevalence of about 4.2% among hallucinogen users, though current estimates are uncertain. Peyote and its mescaline content are specifically listed among the substances linked to this condition. The more severe form, called HPPD II, can be long-lasting or even irreversible, with recurring visual disturbances accompanied by anxiety, panic attacks, and avoidant behavior that interferes with daily life.
People with a history of psychosis, schizophrenia, or other serious psychiatric conditions face elevated risk. Research on hallucinogen-related psychotic episodes has found that people who developed schizophrenia alongside HPPD were more likely to have had distressing, frightening psychedelic experiences. The condition can also arise in people with no psychiatric history, sometimes after just a single use.
Long-Term Cognitive Effects
The best evidence on long-term mescaline use comes from a study of Navajo members of the Native American Church, who use peyote regularly in religious ceremonies. Researchers compared 61 regular peyote users (ages 18 to 45) against a group of former alcoholics and a group with minimal substance use. The peyote group showed no significant deficits on any measure of memory, attention, executive function, or mental health, while the former alcoholic group showed deficits on nearly every test. Total lifetime peyote use within the peyote group had no correlation with cognitive performance.
This is reassuring but comes with an important caveat: these results may not generalize to recreational users. The Native American Church context involves structured ceremonies, community support, and a specific cultural framework. Dose, frequency, setting, and the user’s mental state all influence outcomes, and the controlled ceremonial environment is fundamentally different from unsupervised use.
Drug Interactions
Research on mescaline’s interactions with other drugs is surprisingly thin. Most of the existing studies date to the 1950s and involved small numbers of healthy volunteers. Chlorpromazine, an antipsychotic, was found to dampen mescaline’s effects, which is consistent with how antipsychotics work against other psychedelics. Beyond that, the evidence is limited and often contradictory.
The more relevant concern for modern users involves SSRIs and MAOIs, two common classes of antidepressants. SSRIs work on the same serotonin system that mescaline targets, and MAOIs can dramatically alter how the body processes serotonin-active drugs, potentially increasing their intensity or duration. While formal clinical data on these specific combinations with mescaline is lacking, the pharmacological overlap means combining them carries unpredictable risks. MAOIs in particular are known to intensify the effects of other serotonin-active psychedelics and could theoretically push mescaline’s cardiovascular and psychological effects into dangerous territory.
Legal Status
Mescaline is a Schedule I controlled substance in the United States under the Controlled Substances Act. Federal law provides a specific exemption for the use of peyote by members of the Native American Church as part of religious ceremonies, a protection rooted in the American Indian Religious Freedom Act. Outside of that narrow exemption, possession and distribution of mescaline in any form, whether extracted from peyote, San Pedro cactus, or synthesized in a lab, is a federal crime.
Dose and the Safety Window
In a placebo-controlled clinical trial, researchers tested mescaline hydrochloride at four doses: 100, 200, 400, and 800 mg. The 100 mg dose sat right at the threshold for producing noticeable psychoactive effects. Moderate doses fell in the 178 to 356 mg range. At 400 mg, effects were strong and fully psychedelic. At 800 mg, adverse effects became significant enough that the research team decided against testing a 1,000 mg dose.
This creates a pattern familiar with many psychoactive substances: the margin between a “strong experience” and “substantially unpleasant side effects” is not that wide. A person taking 400 mg gets a powerful psychedelic experience; a person taking twice that gets severe nausea and vomiting on top of an overwhelming psychological state. With natural peyote, where mescaline content varies from button to button, gauging dose with any precision is difficult.